Company news

Scholar Rock Holding Corporation news in 2024

Scholar Rock Holding Corporation's news releases, calls and decks from 2024, newest first.

View company

Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

November 11, 2024

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

November 3, 2024

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

October 31, 2024

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

October 30, 2024

Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

October 21, 2024

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

October 7, 2024

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

October 6, 2024

Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

October 6, 2024

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

September 9, 2024

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

September 3, 2024

Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

August 7, 2024

Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

July 22, 2024

Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

June 23, 2024

Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting

June 2, 2024

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 27, 2024

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

May 21, 2024

Scholar Rock to Host Investor Day on May 22, 2024

May 13, 2024

Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress

May 6, 2024

Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress

March 18, 2024

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

February 14, 2024

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

February 5, 2024

Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia

January 24, 2024

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

January 22, 2024

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024

January 3, 2024

Calls in 2024

Decks in 2024